ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v21i6.2841ppharm-2557Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWСовременный опыт фармакотерапии синдрома раздраженного кишечника у детейModern Experience in Pharmacotherapy of Irritable Bowel Syndrome in Childrenhttps://orcid.org/0000-0001-7308-7280ХавкинА. И.KhavkinAnatoly I.

Хавкин Анатолий Ильич, д.м.н., npoфeccop 

115093, г. Москва, ул. Большая Серпуховская, д. 62 

Anatoly I. Khavkin, MD, PhD, Professor

62, Bolshaya Serpukhovskaya Str., Moscow, 115093

gastropedclin@gmail.comhttps://orcid.org/0000-0001-8364-6066НиколайчукК. М.NikolaychukKirill M.

Николайчук Кирилл Михайлович, студент 

Новосибирск

Kirill М. Nikolaychuk, student

Novosibirsk

k.nikolaichuk@g.nsu.ruhttps://orcid.org/0009-0002-9228-2350ВеременкоA. С.VeremenkoAnastasia S.

Веременко Анастасия Сергеевна, студентка 

Новосибирск

Anastasia S. Veremenko, student

Novosibirsk

a.veremenko@g.nsu.ruhttps://orcid.org/0009-0002-7317-6077ЛевченкоИ. Д.LevchenkoIrina D.

Левченко Ирина Дмитриевна, студентка 

Новосибирск

Irina D. Levchenko, student

Novosibirsk

i.levchenko@g.nsu.ruhttps://orcid.org/0009-0004-1880-9585ПлатоноваП. Я.PlatonovaPolina Ya.

Платонова Полина Яковлевна, студентка 

Новосибирск

Polina Ya. Platonova, student

Novosibirsk

p.platonova@g.nsu.ruhttps://orcid.org/0009-0008-7479-8277НовиковаМ. Ф.NovikovaMaria F.

Новикова Мария Федоровна, студентка

Новосибирск

Maria F. Novikova, student

Novosibirsk

m.novikova2@g.nsu.ruhttps://orcid.org/0009-0004-1138-6049ТумасА. С.TumasArtem S.

Тумас Артем Сергеевич, студент 

Новосибирск

Artem S. Tumas, student

Novosibirsk

a.tumas@g.nsu.ruhttps://orcid.org/0009-0003-0793-4236ВергуноваЕ. Е.VergunovaEkaterina E.

Вергунова Екатерина Евгеньевна, студентка 

Новосибирск

[Ekaterina E. Vergunova, student

Novosibirsk

e.vergunova@g.nsu.ruhttps://orcid.org/0009-0000-5888-0651ЛукичевД. А.LukichevDmitriy A.

Лукичев Дмитрий Алексеевич, студент

Новосибирск

Dmitriy A. Lukichev, student

Novosibirsk

d.lukichev@g.nsu.ruhttps://orcid.org/0009-0007-9699-233XСергеевД. А.SergeevDanil A.

Сергеев Данил Алексеевич, студент

Новосибирск

Danil A. Sergeev, student

Novosibirsk

d.sergeev1@g.nsu.ruhttps://orcid.org/0000-0003-3606-4068ШрайнерЕ. В.ShraynerEvgenia V.

Шрайнер Евгения Владимировна, к.м.н. 

Новосибирск

Evgenia V. Shrayner, MD, PhD

Novosibirsk

sch704@icloud.comНИКИ детства; БелГУРоссияResearch Clinical Institute of Childhood; Belgorod State UniversityRussian FederationНГУРоссияNovosibirsk State UniversityRussian FederationНГУ; ИХБФМ СО РАН; ГК ЦНМТРоссияNovosibirsk State University; Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences; Center for New Medical TechnologiesRussian Federation202410012025216539550Copyright © Хавкин А.И., Николайчук К.М., Веременко A.С., Левченко И.Д., Платонова П.Я., Новикова М.Ф., Тумас А.С., Вергунова Е.Е., Лукичев Д.А., Сергеев Д.А., Шрайнер Е.В., 20242024Хавкин А.И., Николайчук К.М., Веременко A.С., Левченко И.Д., Платонова П.Я., Новикова М.Ф., Тумас А.С., Вергунова Е.Е., Лукичев Д.А., Сергеев Д.А., Шрайнер Е.В.Khavkin A.I., Nikolaychuk K.M., Veremenko A.S., Levchenko I.D., Platonova P.Y., Novikova M.F., Tumas A.S., Vergunova E.E., Lukichev D.A., Sergeev D.A., Shrayner E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/2557

В данном обзоре рассматриваются современные подходы к диагностике и лечению синдрома раздраженного кишечника (СРК) у детей — одного из наиболее распространенных функциональных расстройств ЖКТ. СРК характеризуется хроническими абдоминальными болями, нарушениями моторики кишечника и изменениями стула, что существенно снижает качество жизни пациентов. В статье подробно анализируются патогенетические механизмы СРК, включая роль оси «кишечник – мозг», микробиоты кишечника и нейроэндокринных факторов. Особое внимание уделено фармакотерапии СРК у детей, включая использование антидепрессантов, пробиотиков и растительных компонентов, а также роли корректоров моторной деятельности пищеварительного тракта в купировании симптомов. Рассмотрены современные рекомендации по применению различных классов антидепрессантов с учетом их фармакокинетических и фармакодинамических особенностей. Также анализируются перспективы использования пробиотиков и растительных препаратов в комплексной терапии СРК. Полученные данные подтверждают необходимость персонализированного подхода к лечению СРК с учетом генетических и физиологических особенностей пациентов.

This review examines modern approaches to the diagnosis and treatment of irritable bowel syndrome (IBS) in children, one of the most common functional disorders of the gastrointestinal tract. IBS is characterized by chronic abdominal pain, intestinal motility disorders and stool changes, which significantly reduces the quality of life of patients. The article analyzes in detail the pathogenetic mechanisms of IBS, including the role of the gut–brain axis, gut microbiota and neuroendocrine factors. Special attention is paid to the pharmacotherapy of IBS in children, including the use of antidepressants, probiotics and herbal components, as well as the role of correctors of the motor activity of the digestive tract in relieving symptoms. Modern recommendations on the use of various classes of antidepressants are considered, taking into account their pharmacokinetic and pharmacodynamic characteristics. The prospects of using probiotics and herbal preparations in the complex therapy of IBS are also analyzed. The data obtained confirm the need for a personalized approach to the treatment of IBS, taking into account the genetic and physiological characteristics of patients.

синдром раздраженного кишечникафармакотерапиямикробиота кишечникаось «мозг – кишечник»фармакогеномикаirritable bowel syndromepharmacotherapygut microbiotagut–brain axispharmacogenomicsReferencesAlyasi AS, Altawili MA, Alabbadi AF, et al. Pharmacological Management for Pediatric Irritable Bowel Syndrome: A Review. Cureus. 2023;15(11):e49197. https://doi.org/10.7759/cureus.49197Alyasi AS, Altawili MA, Alabbadi AF, et al. Pharmacological Management for Pediatric Irritable Bowel Syndrome: A Review. Cureus. 2023;15(11):e49197. https://doi.org/10.7759/cureus.49197Halland M, Saito YA. Irritable bowel syndrome: new and emerging treatments. BMJ. 2015;350:h1622. https://doi.org/10.1136/bmj.h1622Halland M, Saito YA. Irritable bowel syndrome: new and emerging treatments. BMJ. 2015;350:h1622. https://doi.org/10.1136/bmj.h1622Lacy BE, Patel NK. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J Clin Med. 2017;6(11):99. https://doi.org/10.3390/jcm6110099Lacy BE, Patel NK. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J Clin Med. 2017;6(11):99. https://doi.org/10.3390/jcm6110099Hyams JS, Di Lorenzo C, Saps M, et al. Functional Disorders: Children and Adolescents. Gastroenterology. 2016:S00165085(16)00181-5. https://doi.org/10.1053/j.gastro.2016.02.015Hyams JS, Di Lorenzo C, Saps M, et al. Functional Disorders: Children and Adolescents. Gastroenterology. 2016:S00165085(16)00181-5. https://doi.org/10.1053/j.gastro.2016.02.015Soares RL. Irritable bowel syndrome: a clinical review. World J Gastroenterol. 2014;20(34):12144–12160. https://doi.org/10.3748/wjg.v20.i34.12144Soares RL. Irritable bowel syndrome: a clinical review. World J Gastroenterol. 2014;20(34):12144–12160. https://doi.org/10.3748/wjg.v20.i34.12144Yu SJ, Lee HS, Gung HJ, et al. IBS Research Study Group of the Korean Society of Neurogastroenterology and Motility. Efficacy of a Restrictive Diet in Irritable Bowel Syndrome: A Systematic Review and Network Meta-analysis. Korean J Gastroenterol. 2022;80(1):6– 16. https://doi.org/10.4166/kjg.2022.014Yu SJ, Lee HS, Gung HJ, et al. IBS Research Study Group of the Korean Society of Neurogastroenterology and Motility. Efficacy of a Restrictive Diet in Irritable Bowel Syndrome: A Systematic Review and Network Meta-analysis. Korean J Gastroenterol. 2022;80(1):6– 16. https://doi.org/10.4166/kjg.2022.014Ng QX, Soh AYS, Loke W, et al. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res. 2018;11:345–349. https://doi.org/10.2147/JIR.S174982Ng QX, Soh AYS, Loke W, et al. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res. 2018;11:345–349. https://doi.org/10.2147/JIR.S174982Rowland I, Gibson G, Heinken A, et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr. 2018;57(1):1–24. https://doi.org/10.1007/s00394-0171445-8Rowland I, Gibson G, Heinken A, et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr. 2018;57(1):1–24. https://doi.org/10.1007/s00394-0171445-8Gill PA, Inniss S, Kumagai T, et al. The Role of Diet and Gut Microbiota in Regulating Gastrointestinal and Inflammatory Disease. Front Immunol. 2022;13:866059. https://doi.org/10.3389/fimmu.2022.866059Gill PA, Inniss S, Kumagai T, et al. The Role of Diet and Gut Microbiota in Regulating Gastrointestinal and Inflammatory Disease. Front Immunol. 2022;13:866059. https://doi.org/10.3389/fimmu.2022.866059Korterink JJ, Diederen K, Benninga MA, Tabbers MM. Epidemiology of pediatric functional abdominal pain disorders: a meta-analysis. PLoS One. 2015;10(5):e0126982. https://doi.org/10.1371/journal.pone.0126982Korterink JJ, Diederen K, Benninga MA, Tabbers MM. Epidemiology of pediatric functional abdominal pain disorders: a meta-analysis. PLoS One. 2015;10(5):e0126982. https://doi.org/10.1371/journal.pone.0126982Rughwani T. Current Awareness and Tools Available for StressInduced IBS in Children. 2024. In: Digital Commons @ Garrisburg University: Website. Available online: https://digitalcommons.harrisburgu.edu/dandt/13. Accessed on August 31, 2024.Rughwani T. Current Awareness and Tools Available for StressInduced IBS in Children. 2024. In: Digital Commons @ Garrisburg University: Website. Available online: https://digitalcommons.harrisburgu.edu/dandt/13. Accessed on August 31, 2024.Chogle A, Mintjens S, Saps M. Pediatric IBS: an overview on pathophysiology, diagnosis and treatment. Pediatr Ann. 2014;43(4):e76–e82. https://doi.org/10.3928/0090448120140325-08Chogle A, Mintjens S, Saps M. Pediatric IBS: an overview on pathophysiology, diagnosis and treatment. Pediatr Ann. 2014;43(4):e76–e82. https://doi.org/10.3928/0090448120140325-08Algera J, Lövdahl J, Sjölund J, et al. Managing pain in irritable bowel syndrome: current perspectives and best practice. Expert Rev Gastroenterol Hepatol. 2023;17(9):871–881. https://doi.org/10.1080/17474124.2023.2242775Algera J, Lövdahl J, Sjölund J, et al. Managing pain in irritable bowel syndrome: current perspectives and best practice. Expert Rev Gastroenterol Hepatol. 2023;17(9):871–881. https://doi.org/10.1080/17474124.2023.2242775Jing F, Zhang J. Metabolic kinetics of 5-hydroxytryptamine and the research targets of functional gastrointestinal disorders. Dig Dis Sci. 2014;59(11):2642–2648. https://doi.org/10.1007/s10620-014-3244-xJing F, Zhang J. Metabolic kinetics of 5-hydroxytryptamine and the research targets of functional gastrointestinal disorders. Dig Dis Sci. 2014;59(11):2642–2648. https://doi.org/10.1007/s10620-014-3244-xChen M, Ruan G, Chen L, et al. Neurotransmitter and Intestinal Interactions: Focus on the Microbiota-Gut-Brain Axis in Irritable Bowel Syndrome. Front Endocrinol (Lausanne). 2022;13:817100. https://doi.org/10.3389/fendo.2022.817100Chen M, Ruan G, Chen L, et al. Neurotransmitter and Intestinal Interactions: Focus on the Microbiota-Gut-Brain Axis in Irritable Bowel Syndrome. Front Endocrinol (Lausanne). 2022;13:817100. https://doi.org/10.3389/fendo.2022.817100Fu R, Chen M, Chen Y, et al. Expression and clinical significance of 5-HT and 5-HT3R in the intestinal mucosa of patient with diarrhea-type irritable bowel syndrome. Exp Ther Med. 2019;17(4):3077–3082. https://doi.org/10.3892/etm.2019.7297Fu R, Chen M, Chen Y, et al. Expression and clinical significance of 5-HT and 5-HT3R in the intestinal mucosa of patient with diarrhea-type irritable bowel syndrome. Exp Ther Med. 2019;17(4):3077–3082. https://doi.org/10.3892/etm.2019.7297Stasi C, Bellini M, Gambaccini D, et al. Neuroendocrine Dysregulation in Irritable Bowel Syndrome Patients: A Pilot Study. J Neurogastroenterol Motil. 2017;23(3):428–434. https://doi.org/10.5056/jnm16155Stasi C, Bellini M, Gambaccini D, et al. Neuroendocrine Dysregulation in Irritable Bowel Syndrome Patients: A Pilot Study. J Neurogastroenterol Motil. 2017;23(3):428–434. https://doi.org/10.5056/jnm16155Kridler J, Kamat D. Irritable Bowel Syndrome: A Review for General Pediatricians. Pediatr Ann. 2016;45(1):e30–e33. https://doi.org/10.3928/00904481-20151208-01Kridler J, Kamat D. Irritable Bowel Syndrome: A Review for General Pediatricians. Pediatr Ann. 2016;45(1):e30–e33. https://doi.org/10.3928/00904481-20151208-01Ford AC, Bercik P, Morgan DG, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology. 2013;145(6):1262–1270.e1. https://doi.org/10.1053/j.gastro.2013.08.048Ford AC, Bercik P, Morgan DG, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology. 2013;145(6):1262–1270.e1. https://doi.org/10.1053/j.gastro.2013.08.048Palsson OS, Whitehead WE, van Tilburg MA, et al. Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. Gastroenterology. 2016:S0016-5085(16)00180-3. https://doi.org/10.1053/j.gastro.2016.02.014Palsson OS, Whitehead WE, van Tilburg MA, et al. Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. Gastroenterology. 2016:S0016-5085(16)00180-3. https://doi.org/10.1053/j.gastro.2016.02.014Singh SV, Ganguly R, Jaiswal K, et al. Molecular signalling during cross talk between gut brain axis regulation and progression of irritable bowel syndrome: A comprehensive review. World J Clin Cases. 2023;11(19):4458–4476. https://doi.org/10.12998/wjcc.v11.i19.4458Singh SV, Ganguly R, Jaiswal K, et al. Molecular signalling during cross talk between gut brain axis regulation and progression of irritable bowel syndrome: A comprehensive review. World J Clin Cases. 2023;11(19):4458–4476. https://doi.org/10.12998/wjcc.v11.i19.4458Appleton J. The Gut-Brain Axis: Influence of Microbiota on Mood and Mental Health. Integr Med (Encinitas). 2018;17(4):28–32.Appleton J. The Gut-Brain Axis: Influence of Microbiota on Mood and Mental Health. Integr Med (Encinitas). 2018;17(4):28–32.Mayer EA, Ryu HJ, Bhatt RR. The neurobiology of irritable bowel syndrome. Mol Psychiatry. 2023;28(4):1451–1465. https://doi.org/10.1038/s41380-023-01972-wMayer EA, Ryu HJ, Bhatt RR. The neurobiology of irritable bowel syndrome. Mol Psychiatry. 2023;28(4):1451–1465. https://doi.org/10.1038/s41380-023-01972-wCerdó T, García-Santos JA, Rodríguez-Pöhnlein A, et al. Impact of Total Parenteral Nutrition on Gut Microbiota in Pediatric Population Suffering Intestinal Disorders. Nutrients. 2022;14(21):4691. https://doi.org/10.3390/nu14214691Cerdó T, García-Santos JA, Rodríguez-Pöhnlein A, et al. Impact of Total Parenteral Nutrition on Gut Microbiota in Pediatric Population Suffering Intestinal Disorders. Nutrients. 2022;14(21):4691. https://doi.org/10.3390/nu14214691Craven LJ, Silverman M, Burton JP. Transfer of altered behaviour and irritable bowel syndrome with diarrhea (IBS-D) through fecal microbiota transplant in mouse model indicates need for stricter donor screening criteria. Ann Transl Med. 2017;5(24):490. https://doi.org/10.21037/atm.2017.10.03Craven LJ, Silverman M, Burton JP. Transfer of altered behaviour and irritable bowel syndrome with diarrhea (IBS-D) through fecal microbiota transplant in mouse model indicates need for stricter donor screening criteria. Ann Transl Med. 2017;5(24):490. https://doi.org/10.21037/atm.2017.10.03De Palma G, Lynch MD, Lu J, et al. Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Sci Transl Med. 2017;9(379):eaaf6397. https://doi.org/10.1126/scitranslmed.aaf6397De Palma G, Lynch MD, Lu J, et al. Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Sci Transl Med. 2017;9(379):eaaf6397. https://doi.org/10.1126/scitranslmed.aaf6397Devanarayana NM, Rajindrajith S. Irritable bowel syndrome in children: Current knowledge, challenges and opportunities. World J Gastroenterol. 2018;24(21):2211–2235. https://doi.org/10.3748/wjg.v24.i21.2211Devanarayana NM, Rajindrajith S. Irritable bowel syndrome in children: Current knowledge, challenges and opportunities. World J Gastroenterol. 2018;24(21):2211–2235. https://doi.org/10.3748/wjg.v24.i21.2211Donnet AS, Hasan SS, Whorwell PJ. Hypnotherapy for irritable bowel syndrome: patient expectations and perceptions. Therap Adv Gastroenterol. 2022;15:17562848221074208. https://doi.org/10.1177/17562848221074208Donnet AS, Hasan SS, Whorwell PJ. Hypnotherapy for irritable bowel syndrome: patient expectations and perceptions. Therap Adv Gastroenterol. 2022;15:17562848221074208. https://doi.org/10.1177/17562848221074208Rexwinkel R, de Bruijn CMA, Gordon M, et al. Pharmacologic Treatment in Functional Abdominal Pain Disorders in Children: A Systematic Review. Pediatrics. 2021;147(6):e2020042101. https://doi.org/10.1542/peds.2020-042101Rexwinkel R, de Bruijn CMA, Gordon M, et al. Pharmacologic Treatment in Functional Abdominal Pain Disorders in Children: A Systematic Review. Pediatrics. 2021;147(6):e2020042101. https://doi.org/10.1542/peds.2020-042101Dwyer JB, Bloch MH. Antidepressants for Pediatric Patients. Curr Psychiatr. 2019;18(9):26–42F.Dwyer JB, Bloch MH. Antidepressants for Pediatric Patients. Curr Psychiatr. 2019;18(9):26–42F.Bonilla S, Nurko S. Focus on the use of antidepressants to treat pediatric functional abdominal pain: current perspectives. Clin Exp Gastroenterol. 2018;11:365–372. https://doi.org/10.2147/CEG.S146646Bonilla S, Nurko S. Focus on the use of antidepressants to treat pediatric functional abdominal pain: current perspectives. Clin Exp Gastroenterol. 2018;11:365–372. https://doi.org/10.2147/CEG.S146646Deodhar M, Rihani SBA, Darakjian L, et al. Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition. Pharmaceutics. 2021;13(2):148. https://doi.org/10.3390/pharmaceutics13020148Deodhar M, Rihani SBA, Darakjian L, et al. Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition. Pharmaceutics. 2021;13(2):148. https://doi.org/10.3390/pharmaceutics13020148Huang X, Li C, Li C, et al. CYP2C19 Genotyping May Provide a Better Treatment Strategy when Administering Escitalopram in Chinese Population. Front Pharmacol. 2021;12:730461. https://doi.org/10.3389/fphar.2021.730461Huang X, Li C, Li C, et al. CYP2C19 Genotyping May Provide a Better Treatment Strategy when Administering Escitalopram in Chinese Population. Front Pharmacol. 2021;12:730461. https://doi.org/10.3389/fphar.2021.730461Maciaszek J, Pawłowski T, Hadryś T, et al. The Impact of the CYP2D6 and CYP1A2 Gene Polymorphisms on Response to Duloxetine in Patients with Major Depression. Int J Mol Sci. 2023;24(17):13459. https://doi.org/10.3390/ijms241713459Maciaszek J, Pawłowski T, Hadryś T, et al. The Impact of the CYP2D6 and CYP1A2 Gene Polymorphisms on Response to Duloxetine in Patients with Major Depression. Int J Mol Sci. 2023;24(17):13459. https://doi.org/10.3390/ijms241713459Ford AC, Wright-Hughes A, Alderson SL, et al. ATLANTIS trialists. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10414):1773–1785. https://doi.org/10.1016/S0140-6736(23)01523-4Ford AC, Wright-Hughes A, Alderson SL, et al. ATLANTIS trialists. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10414):1773–1785. https://doi.org/10.1016/S0140-6736(23)01523-4Nassan M, Nicholson WT, Elliott MA, et al. Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine. Mayo Clin Proc. 2016;91(7):897–907. https://doi.org/10.1016/j.mayocp.2016.02.023Nassan M, Nicholson WT, Elliott MA, et al. Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine. Mayo Clin Proc. 2016;91(7):897–907. https://doi.org/10.1016/j.mayocp.2016.02.023Dean L. Amitriptyline Therapy and CYP2D6 and CYP2C19 Genotype. In: Medical Genetics Summaries. Pratt VM, Scott SA, Pirmohamed M, et al., eds. Bethesda (MD): National Center for Biotechnology Information (US); 2017.Dean L. Amitriptyline Therapy and CYP2D6 and CYP2C19 Genotype. In: Medical Genetics Summaries. Pratt VM, Scott SA, Pirmohamed M, et al., eds. Bethesda (MD): National Center for Biotechnology Information (US); 2017.Radosavljevic M, Svob Strac D, Jancic J, Samardzic J. The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy. Genes (Basel). 2023;14(5):1095. https://doi.org/10.3390/genes14051095Radosavljevic M, Svob Strac D, Jancic J, Samardzic J. The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy. Genes (Basel). 2023;14(5):1095. https://doi.org/10.3390/genes14051095Pirmohamed M. Pharmacogenomics: current status and future perspectives. Nat Rev Genet. 2023;24(6):350–362. https://doi.org/10.1038/s41576-022-00572-8Pirmohamed M. Pharmacogenomics: current status and future perspectives. Nat Rev Genet. 2023;24(6):350–362. https://doi.org/10.1038/s41576-022-00572-8Thümmler S, Dor E, David R, et al. Pharmacoresistant Severe Mental Health Disorders in Children and Adolescents: Functional Abnormalities of Cytochrome P450 2D6. Front Psychiatry. 2018;9:2. https://doi.org/10.3389/fpsyt.2018.00002Thümmler S, Dor E, David R, et al. Pharmacoresistant Severe Mental Health Disorders in Children and Adolescents: Functional Abnormalities of Cytochrome P450 2D6. Front Psychiatry. 2018;9:2. https://doi.org/10.3389/fpsyt.2018.00002Austin-Zimmerman I, Wronska M, Wang B, et al. The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics. Genes (Basel). 2021;12(11):1758. https://doi.org/10.3390/genes12111758Austin-Zimmerman I, Wronska M, Wang B, et al. The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics. Genes (Basel). 2021;12(11):1758. https://doi.org/10.3390/genes12111758Lam D, Ancelin ML, Ritchie K, et al. Genotype-dependent associations between serotonin transporter gene (SLC6A4) DNA methylation and late-life depression. BMC Psychiatry. 2018;18(1):282. https://doi.org/10.1186/s12888-018-1850-4Lam D, Ancelin ML, Ritchie K, et al. Genotype-dependent associations between serotonin transporter gene (SLC6A4) DNA methylation and late-life depression. BMC Psychiatry. 2018;18(1):282. https://doi.org/10.1186/s12888-018-1850-4Taylor MJ, Sen S, Bhagwagar Z. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry. 2010;68(6):536–543. https://doi.org/10.1016/j.biopsych.2010.04.034Taylor MJ, Sen S, Bhagwagar Z. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry. 2010;68(6):536–543. https://doi.org/10.1016/j.biopsych.2010.04.034Jukic M, Milosavljević F, Molden E, Ingelman-Sundberg M. Pharmacogenomics in treatment of depression and psychosis: an update. Trends Pharmacol Sci. 2022;43(12):1055–1069. https://doi.org/10.1016/j.tips.2022.09.011Jukic M, Milosavljević F, Molden E, Ingelman-Sundberg M. Pharmacogenomics in treatment of depression and psychosis: an update. Trends Pharmacol Sci. 2022;43(12):1055–1069. https://doi.org/10.1016/j.tips.2022.09.011Aka I, Bernal CJ, Carroll R, et al. Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children. J Pers Med. 2017;7(4):14. https://doi.org/10.3390/jpm7040014Aka I, Bernal CJ, Carroll R, et al. Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children. J Pers Med. 2017;7(4):14. https://doi.org/10.3390/jpm7040014Lu PL, Velasco-Benítez CA, Saps M. Sex, Age, and Prevalence of Pediatric Irritable Bowel Syndrome and Constipation in Colombia: A Population-based Study. J Pediatr Gastroenterol Nutr. 2017;64(6):e137–e141. https://doi.org/10.1097/MPG.0000000000001391Lu PL, Velasco-Benítez CA, Saps M. Sex, Age, and Prevalence of Pediatric Irritable Bowel Syndrome and Constipation in Colombia: A Population-based Study. J Pediatr Gastroenterol Nutr. 2017;64(6):e137–e141. https://doi.org/10.1097/MPG.0000000000001391Karunanayake A, Devanarayana NM, Rajindrajith S. Early life events in functional abdominal pain disorders in children. PLoS One. 2022;17(11):e0275419. https://doi.org/10.1371/journal.pone.0275419Karunanayake A, Devanarayana NM, Rajindrajith S. Early life events in functional abdominal pain disorders in children. PLoS One. 2022;17(11):e0275419. https://doi.org/10.1371/journal. pone.0275419Koppen IJ, Nurko S, Saps M, et al. The pediatric Rome IV criteria: what’s new? Expert Rev Gastroenterol Hepatol. 2017;11(3):193–201. https://doi.org/10.1080/17474124.2017.1282820Koppen IJ, Nurko S, Saps M, et al. The pediatric Rome IV criteria: what’s new? Expert Rev Gastroenterol Hepatol. 2017;11(3):193–201. https://doi.org/10.1080/17474124.2017.1282820Trinkley KE, Nahata MC. Medication management of irritable bowel syndrome. Digestion. 2014;89(4):253–267. https://doi.org/10.1159/000362405Trinkley KE, Nahata MC. Medication management of irritable bowel syndrome. Digestion. 2014;89(4):253–267. https://doi.org/10.1159/000362405Roohafza H, Pourmoghaddas Z, Saneian H, Gholamrezaei A. Citalopram for pediatric functional abdominal pain: a randomized, placebo-controlled trial. Neurogastroenterol Motil. 2014;26(11):1642–1650. https://doi.org/10.1111/nmo.12444Roohafza H, Pourmoghaddas Z, Saneian H, Gholamrezaei A. Citalopram for pediatric functional abdominal pain: a randomized, placebo-controlled trial. Neurogastroenterol Motil. 2014;26(11):1642–1650. https://doi.org/10.1111/nmo.12444Seetharaman J, Poddar U, Yachha SK, et al. Efficacy of amitriptyline in pediatric functional abdominal pain disorders: A randomized placebo-controlled trial. J Gastroenterol Hepatol. 2022;37(4):685–691. https://doi.org/10.1111/jgh.15765Seetharaman J, Poddar U, Yachha SK, et al. Efficacy of amitriptyline in pediatric functional abdominal pain disorders: A randomized placebo-controlled trial. J Gastroenterol Hepatol. 2022;37(4):685–691. https://doi.org/10.1111/jgh.15765Saps M, Youssef N, Miranda A, et al. Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology. 2009;137(4):1261–1269. https://doi.org/10.1053/j.gastro.2009.06.060Saps M, Youssef N, Miranda A, et al. Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology. 2009;137(4):1261–1269. https://doi.org/10.1053/j.gastro.2009.06.060Crawford J, Tran P, Shaw JS, Shaw RJ. Current Pharmacological Treatments for Childhood-Onset Somatic Symptom and Related Disorders (SSRD) and Functional Gastrointestinal Disorders (FGID). Current Treatment Options in Psychiatry. 2020;7:120–143. https://doi.org/10.1007/s40501-020-00209-9Crawford J, Tran P, Shaw JS, Shaw RJ. Current Pharmacological Treatments for Childhood-Onset Somatic Symptom and Related Disorders (SSRD) and Functional Gastrointestinal Disorders (FGID). Current Treatment Options in Psychiatry. 2020;7:120–143. https://doi.org/10.1007/s40501-020-00209-9Guandalini S, Magazzù G, Chiaro A, et al. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr. 2010;51(1):24–30. https://doi.org/10.1097/MPG.0b013e3181ca4d95Guandalini S, Magazzù G, Chiaro A, et al. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr. 2010;51(1):24–30. https://doi.org/10.1097/MPG.0b013e3181ca4d95Sudha MR, Jayanthi N, Aasin M, et al. Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study. Benef Microbes. 2018;9(4):563–572. https://doi.org/10.3920/BM2017.0129Sudha MR, Jayanthi N, Aasin M, et al. Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study. Benef Microbes. 2018;9(4):563–572. https://doi.org/10.3920/BM2017.0129Francavilla R, Miniello V, Magistà AM, et al. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics. 2010;126(6):e1445–e1452. https://doi.org/10.1542/peds.2010-0467Francavilla R, Miniello V, Magistà AM, et al. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics. 2010;126(6):e1445–e1452. https://doi.org/10.1542/peds.2010-0467Menon J, Thapa BR, Kumari R, et al. Efficacy of Oral Psyllium in Pediatric Irritable Bowel Syndrome: A Double-Blind Randomized Control Trial. J Pediatr Gastroenterol Nutr. 2023;76(1):14–19. https://doi.org/10.1097/MPG.0000000000003622Menon J, Thapa BR, Kumari R, et al. Efficacy of Oral Psyllium in Pediatric Irritable Bowel Syndrome: A Double-Blind Randomized Control Trial. J Pediatr Gastroenterol Nutr. 2023;76(1):14–19. https://doi.org/10.1097/MPG.0000000000003622Shulman RJ, Hollister EB, Cain K, et al. Psyllium Fiber Reduces Abdominal Pain in Children With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial. Clin Gastroenterol Hepatol. 2017;15(5):712–719.e4. https://doi.org/10.1016/j.cgh.2016.03.045Shulman RJ, Hollister EB, Cain K, et al. Psyllium Fiber Reduces Abdominal Pain in Children With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial. Clin Gastroenterol Hepatol. 2017;15(5):712–719.e4. https://doi.org/10.1016/j.cgh.2016.03.045Ogawa N, Nakajima S, Tamada K, et al. Trimebutine suppresses Toll-like receptor 2/4/7/8/9 signaling pathways in macrophages. Arch Biochem Biophys. 2021;711:109029. https://doi.org/10.1016/j.abb.2021.109029Ogawa N, Nakajima S, Tamada K, et al. Trimebutine suppresses Toll-like receptor 2/4/7/8/9 signaling pathways in macrophages. Arch Biochem Biophys. 2021;711:109029. https://doi.org/10.1016/j.abb.2021.109029Karabulut GS, Beşer OF, Erginöz E, et al. The Incidence of Irritable Bowel Syndrome in Children Using the Rome III Criteria and the Effect of Trimebutine Treatment. J Neurogastroenterol Motil. 2013;19(1):90–93. https://doi.org/10.5056/jnm.2013.19.1.90Karabulut GS, Beşer OF, Erginöz E, et al. The Incidence of Irritable Bowel Syndrome in Children Using the Rome III Criteria and the Effect of Trimebutine Treatment. J Neurogastroenterol Motil. 2013;19(1):90–93. https://doi.org/10.5056/jnm.2013.19.1.90Kaneto H, Takahashi M, Watanabe J. The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies. J Pharmacobiodyn. 1990;13(7):448–453. https://doi.org/10.1248/bpb1978.13.448Kaneto H, Takahashi M, Watanabe J. The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies. J Pharmacobiodyn. 1990;13(7):448–453. https://doi.org/10.1248/bpb1978.13.448

The authors declare that there are no conflicts of interest present.